| First Author | Lin YH | Year | 2021 |
| Journal | J Cell Mol Med | Volume | 25 |
| Issue | 14 | Pages | 7089-7094 |
| PubMed ID | 34114734 | Mgi Jnum | J:314225 |
| Mgi Id | MGI:6816059 | Doi | 10.1111/jcmm.16554 |
| Citation | Lin YH, et al. (2021) Loss of MYSM1 inhibits the oncogenic activity of cMYC in B cell lymphoma. J Cell Mol Med 25(14):7089-7094 |
| abstractText | MYSM1 is a chromatin-binding protein, widely investigated for its functions in haematopoiesis in human and mouse; however, its role in haematologic malignancies remains unexplored. Here, we investigate the cross-talk between MYSM1 and oncogenic cMYC in the transcriptional regulation of genes encoding ribosomal proteins, and the implications of these mechanisms for cMYC-driven carcinogenesis. We demonstrate that in cMYC-driven B cell lymphoma in mouse models, MYSM1-loss represses ribosomal protein gene expression and protein synthesis. Importantly, the loss of MYSM1 also strongly inhibits cMYC oncogenic activity and protects against B cell lymphoma onset and progression in the mouse models. This advances the understanding of the molecular and transcriptional mechanisms of lymphomagenesis, and suggests MYSM1 as a possible drug target for cMYC-driven malignancies. |
